$0.177
-0.008 (-4.79%)Zum Schluss
AZTR-News
AZTR-Events
Azitra CEO: Significant Progress in Q2
"The second quarter has marked an exciting evolution for Azitra with the first data from our ATR-COSF program, which provided validation of our strategy to leverage our microbial genetic engineering platform beyond traditional therapeutics," said Francisco Salva, Chief Executive Officer of Azitra. "Combined with the continued advancement of ATR-04 and our recombinant protein initiatives, these accomplishments reflect the breadth of opportunities we are creating in multiple billion dollar markets, including therapeutics, cosmetic ingredients and biotechnology applications. During the quarter, we also continued enrollment of the first cohort in our Phase 1/2 clinical trial evaluating ATR-04 for EGFR inhibitor-associated rash. With six active clinical sites, including MD Anderson Cancer Center, we remain on track to report topline data from the first cohort around year end. Additionally, we are in the process to open eligibility criteria to other cancer treatment related rashes driven by inhibitors along the same EGFR/KRAS/MEK/ERK pathway. EGFR inhibitor-associated rash remains a significant unmet medical need, affecting an estimated 50% to 90% of patients receiving EGFR-targeted cancer therapies and frequently leading to dose reductions, treatment interruptions or discontinuation."
Azitra Phase 1/2 ATR 04 Trial On Track for Topline Data This Year
Azitra says Phase 1/2 ATR 04 trial remains on track for topline data this year
Azitra CEO Discusses Company Strategy and ATR COSF Commercial Potential
In an exclusive interview, AzitraCEO Francisco Salva spoke with The Fly about the company's expanding strategy, the science behind its recombinant protein programs, the commercial potential of ATR COSF, and how the company is redefining its identity beyond precision dermatology.THE COMPANY:Azitra is a microbial genetic engineering company developing products across therapeutics, cosmeceuticals, and biotechnology applications. While its roots are in precision dermatology – including ATR 04 for EGFR inhibitor associated rash – the company is leveraging the same underlying technology to create recombinant proteins for consumer skincare and broader biotech markets."At its core, Azitra is a microbial genetic engineering company," the CEO told The Fly. "What makes us unique is that we're building a platform capable of generating multiple commercial opportunities from the same core technology."UPDATED STRATEGY:Azitra's recently updated corporate strategy reflects a broader view of how its platform can create value. The company remains committed to advancing therapies for patients with unmet medical needs, but it is also accelerating programs with shorter development timelines and larger commercial markets.The March financing enabled this expansion, with ATR COSF emerging as the first example. Originally rooted in therapeutic research on recombinant filaggrin, ATR COSF is now being advanced as a cosmetic ingredient designed to improve the appearance of fine lines and wrinkles. Additional recombinant protein programs, like TEV Protease and T7 RNA Polymerase, further demonstrate the platform's versatility."These initiatives create multiple pathways for growth," the executive said.ATR-COSF:Salva highlighted ATR COSF as "one of the most exciting initiatives enabled by the March financing," and early data supports that enthusiasm.Two preliminary studies evaluated the distribution and functional activity of Azitra's filaggrin domain containing supernatant. The company demonstrated successful, controlled delivery of the domain into the stratum granulosum – the targeted layer of the skin – with increased distribution compared to prior single dose human skin experiments. Additionally, single dose ex vivo studies showed improvements in elasticity and enhanced hydration, reinforcing early signals that ATR COSF may support cosmetic applications as a high value ingredient.The planned clinical study will serve as a proof of concept milestone, assessing safety and early efficacy, including the ingredient's ability to improve fine lines and wrinkles."Successfully demonstrating those attributes would represent an important step toward validating the commercial potential of the program," the executive said. Assuming positive results, Azitra believes ATR COSF could support partnership discussions and commercialization opportunities beginning as early as 2027.NEAR-TERM MILESTONES:Azitra expects a steady cadence of milestones across both its therapeutic pipeline and its expanding platform initiatives. On the clinical side, the company is advancing the Phase 1/2 study of ATR 04 for EGFR inhibitor associated rash, with topline data from the Phase 1 portion expected in the second half of this year.Preparations are also underway for the planned clinical study of ATR COSF, which the company views as an important validation of its move into cosmeceuticals. Beyond these programs, Azitra continues to progress its recombinant protein initiatives, including Tobacco Etch Virus Protease and T7 RNA Polymerase."These programs represent early proof points for our broader microbial genetic engineering capabilities," the executive noted.AN EVOLVING COMPANY:The CEO emphasized the importance of understanding how the company is evolving."Historically, investors have known us as a clinical stage precision dermatology company," the executive said. "What has changed is the breadth of opportunities we're pursuing with our proprietary microbial genetic engineering platforms, which could provide near-term value creation."The same technologies used to create therapeutic candidates are now being applied to cosmeceuticals, recombinant proteins, and biotechnology applications, enabling multiple attractive markets while leveraging a common platform."We believe this creates additional opportunities for generating long term shareholder value, and it's an exciting new chapter for Azitra."Meet the Company is The Fly's recurring series of exclusive short interviews with Executive Officers to offer a deeper look inside the company.
Azitra Announces Skin Study Results Showing Significant Anti-Wrinkle Activity
Azitra announced results from two separate ex vivo human skin tissue studies. The studies evaluated the distribution and anti-wrinkle activity of Azitra's filaggrin domain containing supernatant in two separate experimental studies. The ATR-COSF program utilizes the supernatant from a strain of S. epidermidis engineered to secrete a functional unit of the human filaggrin protein. In the first study, ATR-COSF supernatant was found to provide a positive penetration and distribution profile for rHDfilaggrin in a multiple dose, ex vivo model. The study, which utilized fresh, healthy human skin explants, demonstrated a remarkable increase in rHDfilaggrin delivered through the stratum corneum and into the stratum granulosum layers, compared to single dose previous work. Additionally, improved concentration in the stratum corneum and stratum granulosum layers was seen with the formulated product in comparison to concentrated supernatant alone. The first ex vivo model offers a biologically relevant system for evaluating skin penetration while preserving the architecture of human skin. The healthy human skin explants were first stimulated with TH2 cytokines to reduce the levels of endogenous filaggrin in the samples. The study used a 2% lyophilized supernatant in a hydrogel formulation. rHDfilaggrin penetration in the middle to lower stratum corneum was detected following a single application of the 2% formulation. Increased amounts of rHDfilaggrin were observed with additional applications. Safety testing conducted in accordance with standardized guidelines demonstrated that the 2% supernatant formulation is non-irritating and non-corrosive to the skin and eyes. TH2 cytokine stimulation markedly reduced the presence of keratohyalin granules, resulting in decreased endogenous filaggrin. This reduction facilitates the differentiation and detection of rHDfilaggrin following application. The second ex vivo model utilized defatted human skin explants to assess the effect of the lyophilized rHDfilaggrin supernatant in a hydrogel formulation on human skin elasticity. Concentrations of the supernatant in the hydrogel were varied from 0.0% to 7.5%. Elasticity was measured at 20 hours post application. Skin samples were incubated at 30degreesC. The hydrogel alone results are shown in open circles and the active are in black squares. The hydrogel containing the lyophilized supernatant was active in increasing the elasticity of ex vivo human skin sections in a dose-dependent manner. Minimal and maximum effects in elasticity enhancement were observed in hydrogels containing 0.09% w/w and 7.5% w/w of active ingredient, respectively. Hydrogels containing 0.28% w/w of active ingredient restored ex vivo abdominoplasty skin elasticity to values historically observed in healthy skin. The active treated sample showed approximately two times the elasticity compared to the placebo treated skin sample, highlighting the formulation's potential as a novel cosmetic ingredient for improving skin firmness and resilience.
Azitra Files to Sell 255.7M Shares of Common Stock
Azitra files to sell 255.7M shares of common stock for holders
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.